Skip to content
Screener

Supernus Pharmaceuticals SUPN Oxtellar XR — Total revenues

Other product segments

Qelbree
$77.84M+20.2%
GOCOVRI
$35.24M+14.8%
Royalty, licensing, and other revenues
$29.31M+274%
Collaboration revenue (ZURZUVAE)
$27.64M—
Trokendi XR
$9.48M-26.0%
ONAPGO
$8.38M—
APOKYN
$7.73M-48.4%
Other
$4.67M-45.6%

Similar metrics at other companies

PROG Holdings logo
PRGOther revenue — Total revenues
$39.4M+134%
Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
LanzaTech Global, Inc. logo
LNZABiorefining revenue — Total revenues
$6.98M+145%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.72B+14.3%
Enterprise value$2.57B+13.6%
P/S3.5×-0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Trokendi XR9,47912,801
ONAPGO8,375—
APOKYN7,72814,976
Oxtellar XR7,42210,198
Other(1)4,6668,579
Total net product sales150,753141,988
Collaboration revenue (ZURZUVAE)(2)27,643—
Royalty, licensing, and other revenues29,3097,836

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's oxtellar XR — total revenues?
Supernus Pharmaceuticals (SUPN) reported oxtellar XR — total revenues of $7.42M in Q1 2026.
How has Supernus Pharmaceuticals's oxtellar XR — total revenues changed year-over-year?
Supernus Pharmaceuticals's oxtellar XR — total revenues decreased by 27.2% year-over-year, from $10.2M to $7.42M.
What is the long-term trend for Supernus Pharmaceuticals's oxtellar XR — total revenues?
Over 4 years (2021 to 2025), Supernus Pharmaceuticals's oxtellar XR — total revenues has grown at a -22.1% compound annual growth rate (CAGR), from $110.71M to $40.7M.
What does oxtellar XR — total revenues mean?
This metric represents the total gross revenue generated from the sales of a specific pharmaceutical product within the company's neuroscience portfolio. It serves as a key indicator of the product's market adoption, commercial performance, and contribution to the company's overall top-line growth. Tracking this revenue stream helps investors assess the lifecycle stage and competitive positioning of the therapeutic asset.

Ask your AI about Supernus Pharmaceuticals's oxtellar xr — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude